Clinical trial
A Prospective, Multicentric, Randomized, Double Blind, Placebo Controlled Phase II Clinical Study to Compare the Safety and Efficacy of PMZ-1620 Therapy Along With Standard Supportive Care in Subjects of Mild to Moderate Alzheimer's Disease
NCT04052737 is registered in ClinicalTrials.gov with Pharmazz, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Multicentric, Randomized, Double Blind, Placebo Controlled Phase II Clinical Study to Compare the Safety and Efficacy of PMZ-1620 Therapy Along With Standard Supportive Care in Subjects of Mild to Moderate Alzheimer's Disease
- Lead sponsor
- Pharmazz, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- March 23, 2018
- Completion date
- January 6, 2023
- Enrollment
- 80 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.